Entering text into the input field will update the search result below

Patients with late stage solid tumors respond to Immunomedics' antibody-drug conjugate

Apr. 20, 2015 4:37 PM ETImmunomedics, Inc. (IMMU) StockIMMUBy: Douglas W. House, SA News Editor
  • Data from a 184-subject Phase 1/2 study assessing Immunomedics' (NASDAQ:IMMU) antibody-drug conjugate, sacituzumab govitecan, in patients with epithelial cancers showed significant and durable tumor shrinkage after treatment, including some metastatic triple-negative breast cancer patients whose whose tumors were no longer detectable by computed tomography (two of 12 patients).
  • The interim results were generated from 130 patients having one of four cancer types: breast, lung, esophageal and colorectal. All failed prior therapies. The objective response rates (defined as partial responses) were 26% (n=12) for triple-negative breast cancer (n=46), 32% (n=6) for non-small cell lung cancer (n=19), 30% (n=6) for small cell lung cancer (n=20) and 13% (n=2) for esophageal cancer (n=16). The number of patients represents those that were evaluable at the time of the interim analysis.
  • The disease control rates (responders plus those with stable disease) for the four groups were 74%, 74%, 55% and 56%, respectively. The cancer was deemed stable if the tumor shrank <30% or increased <20%.
  • The company utilizes moderately toxic drugs conjugated to tumor-targeting antibodies instead of highly toxic agents. It believes that this is a more effective method to administer cytotoxic compounds over repeated cycles of treatment.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
IMMU--
Immunomedics, Inc.